(Q81037629)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16091226%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

review article

1 reference

title

Virologic and immunologic response to highly active antiretroviral therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16091226%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

author name string

Lisa P Jacobson

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16091226%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

John P Phair

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16091226%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Traci E Yamashita

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16091226%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

publication date

1 June 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16091226%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

published in

Current HIV/AIDS reports

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16091226%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

volume

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16091226%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16091226%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

page(s)

74-81

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16091226%20AND%20SRC:MED&resulttype=core&format=json

Changes in thymic function with age and during the treatment of HIV infection

5 January 2020

cites work

1 reference

12 December 2020

Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy

1 reference

12 December 2020

CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load

1 reference

12 December 2020

Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study

1 reference

12 December 2020

Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy

1 reference

12 December 2020

HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load

1 reference

12 December 2020

Effects of virologic rebound on CD4 cell counts

1 reference

12 December 2020

Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapy

1 reference

12 December 2020

Clinical, Biologic, and Behavioral Predictors of Early Immunologic and Virologic Response in HIV-Infected Patients Initiating Protease Inhibitors

1 reference

12 December 2020

Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study

1 reference

12 December 2020

Improved survival among HIV-infected individuals following initiation of antiretroviral therapy

1 reference

12 December 2020

Increase and plateau of CD4 T-cell counts in the 3(1/2) years after initiation of potent antiretroviral therapy

1 reference

12 December 2020

Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine

1 reference

12 December 2020

Virologic rebound on HAART in the context of low treatment adherence is associated with a low prevalence of antiretroviral drug resistance

1 reference

12 December 2020

CCR5 delta32 deletion and response to highly active antiretroviral therapy in HIV-1-infected patients

1 reference

12 December 2020

Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group.

1 reference

12 December 2020

Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study

1 reference

12 December 2020

Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection

1 reference

12 December 2020

Association of the CCR5delta32 mutation with improved response to antiretroviral therapy

1 reference

12 December 2020

Decreased recovery of CD4 lymphocytes in older HIV-infected patients beginning highly active antiretroviral therapy

1 reference

12 December 2020

Drug resistance in patients experiencing early virological failure under a triple combination including indinavir

1 reference

12 December 2020

The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy

1 reference

12 December 2020

Long-term outcomes among antiretroviral-naive human immunodeficiency virus-infected patients with small increases in CD4+ cell counts after successful virologic suppression

1 reference

12 December 2020

Fraction of cases of acquired immunodeficiency syndrome prevented by the interactions of identified restriction gene variants

1 reference

12 December 2020

Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment.

1 reference

12 December 2020

Virological and immunological response to HAART therapy in a community-based cohort of HIV-1-positive individuals

1 reference

12 December 2020

High levels of adherence do not prevent accumulation of HIV drug resistance mutations

1 reference

12 December 2020

Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients

1 reference

12 December 2020

Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function

1 reference

12 December 2020

Correlation between self-reported adherence to highly active antiretroviral therapy (HAART) and virologic outcome

1 reference

12 December 2020

The relationship between virus load response to highly active antiretroviral therapy and change in CD4 cell counts: A report from the Women's interagency HIV study

1 reference

12 December 2020

Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression

1 reference

12 December 2020

CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study

1 reference

12 December 2020

Selection by indication of potent antiretroviral therapy use in a large cohort of women infected with human immunodeficiency virus

1 reference

12 December 2020

Virological rebound after suppression on highly active antiretroviral therapy

1 reference

12 December 2020

Predictors of Virological Success and Ensuing Failure in HIV-Positive Patients Starting Highly Active Antiretroviral Therapy in Europe

1 reference

12 December 2020

Analysis of the adult thymus in reconstitution of T lymphocytes in HIV-1 infection

1 reference

12 December 2020

Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors.

1 reference

12 December 2020

Drug-resistant mutants of HIV-1 in patients exhibiting increasing CD4 cell count despite virological failure of highly active antiretroviral therapy.

1 reference

12 December 2020

The Dynamic of Adherence to Highly Active Antiretroviral Therapy: Results From the French National APROCO Cohort

1 reference

12 December 2020

Clinical and immunologic outcome in patients with human immunodeficiency virus infection, according to virologic efficacy in the year after virus undetectability, during antiretroviral therapy

1 reference

12 December 2020

Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia

1 reference

12 December 2020

Time trends in primary HIV-1 drug resistance among recently infected persons

1 reference

12 December 2020

HIV protease inhibitors restore impaired T-cell proliferative response in vivo and in vitro: a viral-suppression-independent mechanism.

1 reference

12 December 2020

Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study

1 reference

12 December 2020

Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators.

1 reference

12 December 2020

CCR5Δ32 and promoter polymorphisms are not correlated with initial virological or immunological treatment response

1 reference

12 December 2020

Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen

1 reference

12 December 2020

Virologic and Immunologic Response to Highly Active Antiretroviral Therapy

1 reference

12 December 2020

Clinical and immunological benefits from highly active antiretroviral therapy in spite of limited viral load reduction in HIV type 1 infection.

1 reference

12 December 2020

10.1007/S11904-004-0011-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16091226%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference